Sofia Heigis appointed CEO of Oncopeptides AB (publ)
August 7, 2023
Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announced that CEO Monica Shaw will be departing the company and transition over to Sofia Heigis who will move from the CCO role to take on the CEO role.
“I am saddened to be leaving Oncopeptides at a time when the promise of Pepaxti for patients with Multiple Myeloma is truly coming to fruition. I am leaving to take up a senior executive role at a large pharmaceutical company but am very glad to be handing over the running of the company to my CCO Sofia Heigis who has been the key driver of the commercialization efforts to date. Sofia will be Oncopeptides CEO as of today and I will secure a smooth transition in the coming weeks. I look forward to seeing the continued growth of Oncopeptides” said Monica Shaw.
Chairman Per Wold-Olsen said, “While I am sad to see Monica leave Oncopeptides, I fully understand the opportunity she is moving for and I am glad we have an excellent internal candidate in Sofia who can continue in the spirit of what has been built over the last months. With the transition to Sofia, Oncopeptides will continue to focus on the commercialization of Pepaxti which has already started in Germany, Austria, Switzerland, and Greece. We look forward to expanding the opportunity of Pepaxti to address the unmet need that continues to exist for patients with Multiple Myeloma.”
“I am truly excited to continue my journey at Oncopeptides, moving from the CCO role where I have built our commercial organization to the CEO role where I will continue our drive to become a profitable company. With our flagship product Pepaxti we have an opportunity to support patients with a product that provides efficacy, tolerability without compromise of quality of life” says Sofia Heigis.
For more information, please contact:
David Augustsson, Director of Corporate Affairs, Oncopeptides AB (publ)
Cell phone: +46 76 229 38 68
This information is information that Oncopeptides is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-08-07 15:07 CEST.
Oncopeptides is a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat hematological diseases. The company uses its proprietary Peptide Drug Candidate platform (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells.
Pepaxti® (melphalan flufenamide, also called melflufen) has been granted Marketing Authorization, in the European Union, the EEA-countries Iceland, Lichtenstein and Norway, as well as in the UK. Pepaxti is indicated in combination with dexamethasone for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-CD38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. For patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation. Melflufen has been granted accelerated approval in the US under the trade name Pepaxto®. The drug is currently not marketed in the US.
Oncopeptides is developing several new compounds based on its proprietary technology platforms and is listed on the Small Cap segment on Nasdaq Stockholm with the ticker ONCO.